Cargando…

Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice

Treating large established tumors is challenging for dendritic cell (DC)-based immunotherapy. DC activation with tumor cell-derived exosomes (TEXs) carrying multiple tumor-associated antigen can enhance tumor recognition. Adding a potent adjuvant, high mobility group nucleosome-binding protein 1 (HM...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Bingfeng, Qi, Han, Lu, Zhen, Chen, Lu, Sun, Bo, Yang, Rong, Zhang, Yang, Liu, Zhili, Gao, Xianjun, You, Abin, Wu, Li, Jing, Renwei, Zhou, Qibing, Yin, HaiFang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156382/
https://www.ncbi.nlm.nih.gov/pubmed/32286296
http://dx.doi.org/10.1038/s41467-020-15569-2
Descripción
Sumario:Treating large established tumors is challenging for dendritic cell (DC)-based immunotherapy. DC activation with tumor cell-derived exosomes (TEXs) carrying multiple tumor-associated antigen can enhance tumor recognition. Adding a potent adjuvant, high mobility group nucleosome-binding protein 1 (HMGN1), boosts DCs’ ability to activate T cells and improves vaccine efficiency. Here, we demonstrate that TEXs painted with the functional domain of HMGN1 (TEX-N1ND) via an exosomal anchor peptide potentiates DC immunogenicity. TEX-N1ND pulsed DCs (DC(TEX-N1ND)) elicit long-lasting antitumor immunity and tumor suppression in different syngeneic mouse models with large tumor burdens, most notably large, poorly immunogenic orthotopic hepatocellular carcinoma (HCC). DC(TEX-N1ND) show increased homing to lymphoid tissues and contribute to augmented memory T cells. Importantly, N1ND-painted serum exosomes from cancer patients also promote DC activation. Our study demonstrates the potency of TEX-N1ND to strengthen DC immunogenicity and to suppress large established tumors, and thus provides an avenue to improve DC-based immunotherapy.